ES2139373T3 - Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. - Google Patents
Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa.Info
- Publication number
- ES2139373T3 ES2139373T3 ES96924952T ES96924952T ES2139373T3 ES 2139373 T3 ES2139373 T3 ES 2139373T3 ES 96924952 T ES96924952 T ES 96924952T ES 96924952 T ES96924952 T ES 96924952T ES 2139373 T3 ES2139373 T3 ES 2139373T3
- Authority
- ES
- Spain
- Prior art keywords
- sub
- alcoil
- hydrogen
- replaced
- alcoiloxi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229950008696 farnesil Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- QKDLQFSLLCQTOH-UHFFFAOYSA-N Trichodonin Natural products C1C(O)C2C3(COC(=O)C)C(C=O)C(C)(C)CCC3OC(=O)C22C(=O)C(=C)C1C2 QKDLQFSLLCQTOH-UHFFFAOYSA-N 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- LYXFCGCYJQCSRL-UHFFFAOYSA-N OOSO Chemical group OOSO LYXFCGCYJQCSRL-UHFFFAOYSA-N 0.000 abstract 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical compound C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/72—4,7-Endo-alkylene-iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NUEVOS PRODUCTOS DE FORMULA GENERAL (I), PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS INCORPORAN. EN LA FORMULA GENERAL (I), R REPRESENTA UN RADICAL DE FORMULA GENERAL - (CH SUB,2}) SUB,M} - X SUB,1} - (CH SUB,2}) SUB,N} Z, DONDE X SUB,1} = SIMPLE ENLACE U O O S, M = 0 O 1 Y N = 0, 1 O 2, PUDIENDO LOS RADICALES CH SUB,2} SER SUSTITUIDOS POR GRUPOS CARBOXI, ALCOXICARBONIL, CARBAMOIL, ALCOILCARBAMOIL, DIALCOILCARBAMOIL, AMINO, ALCOILAMINO O DIALCOILAMINO, Y Z REPRESENTA CARBOXY, COOR SUB,4} (R SUB,4} = ALCOIL) O CON (R SUB,5}) (R SUB,6}) (R SUB,5} = HIDROGENO O ALCOIL), R SUB,1} = HIDROGENO O ALCOIL EVENTUALMENTE SUSTITUIDO, O BIEN R SUB,5} = HIDROGENO O ALCOIL Y R SUB,6} = HIDROXI, ALCOILOXI EVENTUALMENTE SUSTITUIDO, O AMINO, O PO (OR SUB,7}) SUB,2} (R SUB,7} = HIDROGENO O ALCOIL), O UN RADICAL - NH - CO - T (T = HIDROGENO O ALCOIL) EVENTUALMENTE SUSTITUIDO, O BIEN UN RADICAL (A). R SUB,1} Y R SUB,2} = HIDROGENO O HALOGENO O ALCOIL, ALCOILOXI EVENTUALMENTE SUSTITUIDO, OBIEN R SUB,1} Y R SUB,2} SITUADOS EN ORTO UNO CON RESPECTO A OTRO, FORMAN UN HETEROANILLO QUE INCLUYE 1 O 2 HETEROATOMOS EVENTUALMENTE SUSTITUIDOS, O BIEN R SUB,1} = HIDROGENO O HALOGENO O ALCOIL, ALCOILOXI EVENTUALMENTE SUSTITUIDO, Y R SUB,2} = TIOALCOIL; R SUB,3} = HIDROGENO O HALOGENO O ALCOIL, ALCENIL, ALCOILOXI, ALCOILTIO, CARBOXI O ALCOILOXICARBONIL; X = O O S O - NH -, - CO -, METILENO, ETILENO, ALCOILIDENO O 1,1 - CICLOALCOIL, E Y = O O S. LOS NUEVOS PRODUCTOS DE FORMULA GENERAL (I) SON INHIBIDORES DE LA FARNESIL TRANSFERASA, QUE PRESENTAN NOTABLES PROPIEDADES ANTITUMORALES Y ANTILEUCEMICAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9508296A FR2736641B1 (fr) | 1995-07-10 | 1995-07-10 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2139373T3 true ES2139373T3 (es) | 2000-02-01 |
Family
ID=9480830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96924952T Expired - Lifetime ES2139373T3 (es) | 1995-07-10 | 1996-07-08 | Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5936097A (es) |
| EP (1) | EP0839133B1 (es) |
| JP (1) | JPH11511123A (es) |
| KR (1) | KR19990028856A (es) |
| CN (1) | CN1096448C (es) |
| AR (1) | AR003143A1 (es) |
| AT (1) | ATE185341T1 (es) |
| AU (1) | AU712194B2 (es) |
| BR (1) | BR9609440A (es) |
| CA (1) | CA2224414A1 (es) |
| CO (1) | CO4700457A1 (es) |
| CZ (1) | CZ291620B6 (es) |
| DE (1) | DE69604588T2 (es) |
| DK (1) | DK0839133T3 (es) |
| EA (1) | EA000797B1 (es) |
| ES (1) | ES2139373T3 (es) |
| FR (1) | FR2736641B1 (es) |
| GR (1) | GR3031409T3 (es) |
| IL (1) | IL122812A (es) |
| MA (1) | MA23929A1 (es) |
| MX (1) | MX9800262A (es) |
| MY (1) | MY114792A (es) |
| NO (1) | NO309565B1 (es) |
| NZ (1) | NZ313211A (es) |
| PE (1) | PE11898A1 (es) |
| PL (1) | PL324430A1 (es) |
| SK (1) | SK282250B6 (es) |
| TN (1) | TNSN96098A1 (es) |
| TW (1) | TW438792B (es) |
| UY (1) | UY24276A1 (es) |
| WO (1) | WO1997003050A1 (es) |
| ZA (1) | ZA965868B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757855B1 (fr) * | 1996-12-30 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US6013662A (en) | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| US6124465A (en) * | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| CA2315144A1 (fr) * | 1997-12-23 | 1999-07-08 | Patrick Mailliet | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
| FR2772764B1 (fr) * | 1997-12-23 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| FR2796641B1 (fr) | 1999-07-22 | 2001-09-21 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| PE20070427A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| ES2431163T3 (es) | 2007-03-01 | 2013-11-25 | Novartis Ag | Inhibidores de PIM quinasa y métodos para su uso |
| ES2452349T3 (es) | 2007-05-21 | 2014-04-01 | Novartis Ag | Inhibidores de CSF-1R, composiciones, y métodos de uso |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN103080093A (zh) | 2010-03-16 | 2013-05-01 | 达纳－法伯癌症研究所公司 | 吲唑化合物及其应用 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CA2806112C (en) | 2010-07-28 | 2023-03-21 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2699568A1 (en) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP6630742B2 (ja) | 2015-08-17 | 2020-01-15 | クラ オンコロジー， インコーポレイテッド | ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法 |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| EP3534885B1 (en) | 2016-11-03 | 2021-01-20 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in treating cancer |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| EP4303246A1 (de) | 2022-07-04 | 2024-01-10 | Covestro Deutschland AG | Polyisocyanatgemisch |
| WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492372A1 (fr) * | 1980-10-21 | 1982-04-23 | Cird | Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| EP0730605A1 (en) * | 1993-11-05 | 1996-09-11 | Warner-Lambert Company | Substituted di- and tripeptide inhibitors of protein:farnesyl transferase |
-
1995
- 1995-07-10 FR FR9508296A patent/FR2736641B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-03 MA MA24302A patent/MA23929A1/fr unknown
- 1996-07-04 PE PE1996000510A patent/PE11898A1/es not_active Application Discontinuation
- 1996-07-05 TW TW085108158A patent/TW438792B/zh not_active IP Right Cessation
- 1996-07-08 EA EA199800118A patent/EA000797B1/ru not_active IP Right Cessation
- 1996-07-08 DK DK96924952T patent/DK0839133T3/da active
- 1996-07-08 US US08/981,840 patent/US5936097A/en not_active Expired - Fee Related
- 1996-07-08 AT AT96924952T patent/ATE185341T1/de not_active IP Right Cessation
- 1996-07-08 BR BR9609440A patent/BR9609440A/pt not_active Application Discontinuation
- 1996-07-08 WO PCT/FR1996/001062 patent/WO1997003050A1/fr not_active Ceased
- 1996-07-08 IL IL12281296A patent/IL122812A/en not_active IP Right Cessation
- 1996-07-08 DE DE69604588T patent/DE69604588T2/de not_active Expired - Fee Related
- 1996-07-08 JP JP9505557A patent/JPH11511123A/ja active Pending
- 1996-07-08 CA CA002224414A patent/CA2224414A1/fr not_active Abandoned
- 1996-07-08 CN CN96195415A patent/CN1096448C/zh not_active Expired - Fee Related
- 1996-07-08 EP EP96924952A patent/EP0839133B1/fr not_active Expired - Lifetime
- 1996-07-08 MX MX9800262A patent/MX9800262A/es not_active IP Right Cessation
- 1996-07-08 SK SK26-98A patent/SK282250B6/sk unknown
- 1996-07-08 KR KR1019980700157A patent/KR19990028856A/ko not_active Ceased
- 1996-07-08 UY UY24276A patent/UY24276A1/es not_active IP Right Cessation
- 1996-07-08 NZ NZ313211A patent/NZ313211A/xx unknown
- 1996-07-08 PL PL96324430A patent/PL324430A1/xx unknown
- 1996-07-08 ES ES96924952T patent/ES2139373T3/es not_active Expired - Lifetime
- 1996-07-08 AU AU65224/96A patent/AU712194B2/en not_active Ceased
- 1996-07-08 CZ CZ199854A patent/CZ291620B6/cs not_active IP Right Cessation
- 1996-07-09 TN TNTNSN96098A patent/TNSN96098A1/fr unknown
- 1996-07-10 ZA ZA965868A patent/ZA965868B/xx unknown
- 1996-07-10 AR ARP960103511A patent/AR003143A1/es unknown
- 1996-07-10 MY MYPI96002848A patent/MY114792A/en unknown
- 1996-07-10 CO CO96036152A patent/CO4700457A1/es unknown
-
1998
- 1998-01-09 NO NO980094A patent/NO309565B1/no unknown
-
1999
- 1999-10-07 GR GR990402001T patent/GR3031409T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2139373T3 (es) | Derivados de 4,9-etano-benzo(f)isoindol como inhibidores de farnesil transferasa. | |
| ES2121836T3 (es) | Aminoguanidinas. | |
| ES2072779T3 (es) | Derivados aminoacidos anfoteros. | |
| ES2062460T3 (es) | Nuevos derivados de la isoindolona, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2143187T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2150150T3 (es) | Derivados de lactona de derivados de 17-beta-carboxi, carbonato y amida androstano. | |
| MX9203338A (es) | Nuevos derivados del oxico a_nor-esteroide-3-carboxilico. | |
| ES2260933T3 (es) | Derivados del acido de tiazolina. | |
| ES2066808T3 (es) | Derivados de quinoleina, su produccion y uso. | |
| MX9400341A (es) | Derivados de los acidos quinolon- y naftiridon-carboxilicos, procedimiento para su obtencion y agentes antibacterianos y aditivos para piensos que los contienen. | |
| ES2040879T3 (es) | Procedimiento de preparacion de derivados pirimidinilaminicos de piperidina. | |
| ATE120764T1 (de) | Modifizierte polymere mit gemischten hydrophobischen gruppen. | |
| ES2099755T3 (es) | Derivados tripeptidicos de trifluorometilcetona. | |
| ES2159734T3 (es) | Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular. | |
| DE3581768D1 (de) | Tensidepraeparate. | |
| ATE7138T1 (de) | Verfahren zur herstellung von 1,5-didesoxy-1,5imino-d-glucitol und dessen n-derivaten. | |
| ATE118580T1 (de) | Bauplatte und verfahren zur herstellung. | |
| ES2148758T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. | |
| ES2110423T3 (es) | Composiciones polimericas autoextinguentes. | |
| MX9800370A (es) | Derivados n-sustituidos del 4-hidroxiindol y composiciones de tintura de fibras queratinicas que los contienen. | |
| CO4980887A1 (es) | Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico | |
| ES2095068T3 (es) | Peroxicarbonatos polimericos y procedimiento para prepararlos. | |
| ES2058177T3 (es) | Nuevos derivados de alcanosulfonanilida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2057679T3 (es) | Piridinas substituidas. | |
| ES2151155T3 (es) | Nuevos taxoides, su preparacion y las composiciones farmaceuticas que les contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 839133 Country of ref document: ES |